Everyone. Hi, I'm Ashish Sabadra, and I cover information services company at RBC Capital Markets. We are excited to host Clarivate's management team. Thank you for giving us this opportunity. Matti, if you want to kick it off with theâ
Ashish, thank you for hosting us today. This is an important point in the Clarivate transformation. Over the last two years, I've been the CEO for two years, we've taken some very meaningful steps, strengthening and simplifying the company. We rationalized the portfolio. We completed the divestiture of Life Sciences & Healthcare, significantly increased the subscription base and the revenue to 93% from 79%. We had some substantial progress strengthening our balance sheet. You'll hear more about this one. At the same time, we have sharpened our go-to-market and execution, particularly around AI. We've introduced more than 80 different product or AI-enabled product that we believe will bring the company to a better and improved organic growth. We enter to the next phase of the company, more focused, centered around the two leading IP and A&G sectors that we have.
Clear path to sustainability, organic growth, and long-term shareholder value. Thank you again for hosting us today here, Ashish, and looking forward to the conversation.
Sounds great. Thanks for those prepared remarks. That would be a good segue into my question. You talked aboutâ
Yeah
âyour AI initiatives, around 80 agents. Can you talk about how do you think about that driving better value proposition for your customers, but also your ability to monetize some of those AI agents?
No, definitely. We went into a journey introducing AI product. I mean, we've been in the AI for two or three years. We started with creating a small focus group of AI, and we created a center of excellence for AI introduction. Ever since, we have been product by product using the same methodology. We've done this in the mind of with AI introduction, with the 80 different products that are now AI-enabled. We will drive better retention rate for our customers. That's key for us. Let's not forget, we are running $2 billion business. It's 93% of recurring. So improving retention, it's very important for us. So through AI introduction and AI enabling our product line, we've managed to increase, and we are constantly increasing the retention rate. We are now at 94% retention for our customer base.
It's also the AI introduction of the product allow us to increase the upsell opportunities, win new logos over time. So we are pretty upbeat about we believe we can grow the organic revenue to a better market position. Yeah.
That's very helpful, color. We'll talk about more of your AI initiatives as we go through individual segment. I wanted to just first start off at a higher level, talking about the organic growth. Organic growth improved 30 basis points to 1.8%. You've talked about pricing and volume as levers. Can you just help us understand how do we think about the pricing versus the volume dynamic?
No, I think ACV, we see ACV as a great. This is the leading indicator for the growth of the company, the ACV. We've been on a journey improving ACV through better retention, through better product introduction, so more and more AI, winning new logo. Yes, it's also supported by price increase.
Okay, that's helpful. Thanks for clarifying. I meant ACV, not revenue, so ACV growth improving. Just in terms of restructuring, as you said, you've done a number of restructuring. You've completed your Life Sciences & Healthcare divestiture. Most of the A&G book wind-down is behind you. What is remaining in terms of any inorganic disposals in 2027?
Nothing significant is coming up. We are very pleased with the progress on the divestitures. We walk away from the one-time books, the one-time files. It was choppy. It wasn't really predictable, and it was really a great cash flow, so walk away with this. We've run a process to sell the life science business. We're very pleased with the outcome. We closed the deal. We just paid down the debt, and we are making improvement on the ratio of the debts to EBITDA. So we're pleased. We do have some nominal small things that we want to further divest, but it's nothing significant.
Okay, that's very helpful. You had previously talked about taking A&G to 3%-4% revenue growth and IP to 4%-5% revenue growth. Are those still reasonable targets?
Definitely. Definitely. This is a reasonable target. A&G is closer to target, so we are going to end up the year with 2% ACV growth for 2026. We definitely see us going to mid-single digit on both segments over time. This is definitely the objective.
That is great. Maybe we can drill down further on the A&G or IP side first. If you can just talk about the health of the IP or patents in force market. How is that?
It is flat to growing, low single digit. IP, patents in force is flat to growing low single digit. But I think I want to take a bigger perspective of the IP business.
We are very unique in the IP area. We are the only vendor that are actually setting the three type of services that we provide. The annuity business, let us not forget that annuity business is not going to be disrupted by AI. This is a must-have, critical, non-deferrable, non-discretionary service to renew the patent. We actually renewing the patents of the top corporate around the world that actually giving us a patent book and say, "Go renew it in 200 different jurisdiction." That is a great business. It is tech-enabled services. It is not really information services. So we are in the business of renewing patent. This is half of our IP business, renewing the business. On top of this, we have the software, the IPMS software that support. It is like a small ERP system, or basically not that small, an ERP system for IP.
Then we have the intelligent business. So we have annuities, so annuities, that is the patent renewals, the software, and the intelligence, and we are the only vendor and we are the biggest. It is a good business. It went off track in the last years. With Simon coming back with all his experience, Simon has been running CPA for five years. He managed to grow the business with his passion and with knowledge and with the momentum from AI, as we believe we can take the business back to mid-single digit over time.
That is great. We have already started to see that, right? IP ACV turned positive for the first time in several years. Can you help understand what really drove that? How much of it was retention, pricing, new logos?
Yeah, there is a combination of factors there, As hish, and as Matti mentioned, with Simon coming back in, he knows that business well. He has deep relationships in there, and it was a critical priority for him to say, "Look, we want to grow, but first we had to get it to positive, and then from positive, we can get it to growth." So the real focus there was a couple fronts. It was on retention, then going out and attracting new business as well, and then just doing what we can from a price perspective. So, as you said, we were pleased. It was the first quarter in, I think, 3+ years that we had seen ACV for the IP business return to growth. It was humble. We expect to see that continue to grow here in the future.
That is great. As you mentioned, or both of you have mentioned, Simon coming on, there were also some organizational changes that he did. Can you just talk about any kind of organizational changes and how that positions that business going forward?
Yeah. Simon has been in the business for 20 years, five years as the lead of the business, just coming back. He run his own value creation plan. He's done an assessment for the product, he's done an assessment for the team, and he decided to accelerate two things. One is the go-to-market.
His decision, and I highly support it, you've seen this organization to cut the GTM into two, North America and international. Actually, it's working well so far because of the new extra attention that will go to GTM. But Simon has also done some other changes, and one of them is the acceleration and the extra attention, the introduction of IPOne. IPOne is, in fact, a game-changer for the IP segment. Let's not forget, as I mentioned before, we have annuities, software, and intelligence. And IPOne started as a next-generation intelligence solution. We have the underlying data for trademarks, for patent, and for litigation data. We put everything behind one native-born AI capabilities, and here we got IPOne. This is how it started. We have 40 development partner for that. It's already in market. And I think you go beyond this ambitious behind IP is going beyond just intelligence.
It's also providing some agentic capabilities to our customers. For example, if an IP expert need to do a freedom to operate analysis, he can just go into IPOne and do this using the agentic capabilities of IPOne on one hand and the data assets on the other hand. So that's very excited about it. We'll hear more and more about this, and IPOne is going to be a game-changer for IP.
That's great. That was going to be my next follow-up question on IPOne. Is the pilot launch in November? Has it launched already? The GA, is that first quarter? Are you still on track?
Yeah, definitely. Yeah. There's something to say about IPOne that this is available in two different flavors.
Okay.
One is we allow customers to use our own IPOne application with the underlying dataâ
Yeah
âand with our own AI capabilities.
Yes.
But we also enable IPOne through the generic LLM.
Microsoft Copilot, Anthropic, and othersâ
Yeah
âpeople will be able to use IPOne through those third-party generic LLMs without compromising our data. This is key. We can do that. We keep the data. We do not give the data to the LLMs.
That'sâ
It is just going to be done through MCPs.
Okay. Okay. No, that is helpful. You obviously talked about 40+ development partners. Can you talk about the pipeline, the customer pipeline? How many people, how many companies are part of the initial pilot, but also the customer pipeline for IPOne?
No, there's a lot of exciting about IPOne.
Yeah.
I think we mentioned in public that we have 151 customers. Look at it, but it's growing. There's a big momentum. I'm a big fan of momentum. There's a lot of excitement. We are going for a long time.
Yeah.
We are actually going on the offense with IP as opposed to what was done here before and opened the doors. In fact, there are some customers that over the years have left us, they're now knocking back on our doors to hear more and to explore the opportunity to license IPOne. That's a big change.
That's great.
Yeah.
As you mentioned, there is opportunity for you to win new business, like win-backs, new logos. Is there also an opportunity for you to upsell or cross-sell into your existing customer base? When they use IPOne, can they use a broader set of your products?
Definitely. IPOne is three things. One is new ACV dollars. Secondly, it is helping us with the renewals.
Yes.
The Derwent renewals are going to do better because we are implementing IPOne in the Derwent environmentâ
Yes
âincluding the agentic capabilities.
Yeah.
Then thirdly, it increased our competitiveness of our product with the agentic AI capabilities of IPOne.
That's great. Then maybe just on pricing, can you talk about your pricing strategy within IP? How do you think about pricing opportunity there?
Yeah, the price is an important component of our ability to grow the ACV or the annual contract value. So, that pricing component, we look at it on an annual basis. Now Simon leading the team meets with the product teams and the go-to-market teams, and really looks at it from what are the dynamics and what are the environment they're seeing out there in the marketplace, and then they'll set a target for the coming year. We've talked about that we tried to achieve around the 3% price on an annual basis. We're tracking towards that for this year, and we'll look to do something similar or better for the coming year.
Okay. That's great. Just switching gears, talking about A&G. A&G, again, Matti, as you pointed out, it's going to deliver 2% growth by the end of this year. It had 2% subscription growth in 3Q 2026. Can you just talk about the organic growth trajectory from here on, without necessarily giving guidance, but just how do we think about the tailwinds for the business going forward?
No, it's a very First of all, just to reiterate that A&G is a very strong We have some very strong offering on A&G.
Sure.
The Web of Science, Web of Science Research Intelligence. Web of Science Research Intelligence is our new offering for intelligence on top of Web of Science, and helping us again with new ACVs, retention, and the competitive Web of Science. We're pretty upbeat about the opportunity of Web of Science going forward. Strong offering there, strong offering on the content side as well, with again, with new AI capabilities, new product expansion and extension. The ERP from [libraries], we feel good about the trajectory, and we believe we can go to mid-single digits over time. Yeah.
That's great. Can you just talk about the state of the budget for your A&G customers? How are the budgets shaping up for next year?
It's stable. Yes, there are some concerns in different jurisdictions, but let's not forget, those are mission-critical solution. We were smart to move away from the one-time, or this one-time books, one-time pass that we've done in the past are all gone. We are left with mission-critical subscription-based product, which helping us on the retention and on the growth of A&G. So we feel good about it, yeah.
Okay. Matti, you obviously mentioned from a product perspective, the Web of Science Research Intelligence product, that gaining a lot of traction. You have talked about securing 100+ institutional wins and a $20 million pipeline. The question is, what is really driving that momentum? You obviously talked about, is it the product, the product that is resonating with your customer? What is driving that kind of strong momentum? Are these competitive wins, or are these customers that historically have not used your product? Any color on those fronts?
We took a decision. We have some small legacy products within the research environment. We took an approach about a year plus ago saying, "Let us cannibalize our own base using all those small point solution and introduce more comprehensive new AI-born product with necessary uplift, because we want to increase the ACV." We set up and develop a partnership with a lot of different customers, end up with Web of Science Research Intelligence. There is a lot of excitement and a lot of momentums. The beauty of this, we sell our customers in 25 different countries.
It is kind of amazing to think that something that we just introduced about six months ago, over 100 customers and counting in 25 locations, it means that we are doing something right with Web of Science Research Intelligence, again, helping us to retain Web of Science as well, and for Web of Science to be more competitive.
That is great color. You obviously talked about embedding AI capabilities within that product. Can you just give some color around what kind of AI capabilities does it offer and how that is driving better customer value proposition?
Agentic capabilities, we do the job, we helping the customer to do the job. First of all, the intuition, everything today is conversational AI. This is one side of it. Then we let the machine do the work for us with the agentic capabilities. Different use cases for different product, if it's IPOne, if it's Web of Science Research Intelligence. We're also now implementing existing other products as well, agentic capabilities to help people do the job.
Okay. No, that's helpful. Then just on a similar topic of AI and agentic AI, can you talk about how you're enabling Clarivate data being available through, let's say, Microsoft Copilot, through the IPOne connector? Can you just talk about how you're enabling better consumption of your data through different LLMs as well as Microsoft Copilot?
First of all, we do not give the data to the LLM.
Yes.
It's data which is proprietary to us, is fundamental to us. We do not compromise. Customers can decide if they want to consume our data through our own application.
Yeah.
For example, IPOne or Web of Science, or if they want to do this through third party, like through the generic LLMs, like OpenAI, Microsoft Copilot, or Anthropic. That is for the customer to decide. Some will decide. Our belief that the bigger customer may want to consume this through their own corporate, through their own enterprise license of AI, and the smaller customers, the medium-sized, the smaller customers will going to consume our data through our own AI capabilities. So traction is from both sides.
That is great.
We do this obviously through MCPs.
Yeah. No, that was going to be my follow-up question. Is this through MCP? If it is, then how do you charge for that MCP compared to, like, if the customer was getting this data through API versus MCP? Do you charge more for it, or how have you seen consumption go up with the customer consuming it through MCP?
I think it's evolving. It's still evolving. It's the new thing that we are actually experimenting with customers and the feedback and helping, some help that we do take from third party. Definitely it's an evolving. Yes, definitely it's a new revenue stream for us. Yes.
Okay. No, that's very helpful. We've talked a lot about implementing AI solution and customer-facing, but can you also talk about leveraging AI internally to drive efficiency?
Yes, no, this is a really good question, Ashish. I think, when this whole agentic AI journey started a couple years ago, we were first and foremost focused on it from a product perspective, and that's what you kind of heard from us early on. But we started to work on that from an internal perspective as well, and I think that's some of the efficiencies we've gained from that over the past couple of years have helped with the margin expansion that you're seeing this year. But we believe there's continued opportunity, especially in the areas of software development, content aggregation, or contact or content cleansing. There's opportunities from finance and other opportunities across the shared service functions to be more efficient. As we do that and as we gain capabilities there, in some cases it allows us to redeploy to higher value-added function or support.
It's all in the name of how do we better support the commercial teams to drive that organic revenue growth.
Okay. No, that's very helpful. When you think about the margins, right? Margins in the third quarter were close to 45%, which is very much closer to your adjusted EBITDA targets. How do you think about margin expansion opportunities going forward?
Yeah, no, we've been working hard to get to this, I'll call it this approximate 45% level, and that's been an important place and part of a journey for us to get to. Now as we've done the work over these past couple of years, as we've also turned some of our revenue products and offerings to a growth profile, the key for us now is really to say, how do we grow from low digits or barely flat now to where we want to be in the future, as you talked about with Matti when we started. We want to maintain that margin, but these next couple years, we really want to focus on accelerating and growing organically. We'll continue to maintain the margin where it's at.
We think there's plenty of opportunity to maintain margin and adequately invest and give our sales teams, our product teams, the commercial teams opportunities to see accelerated organic revenue growth.
That's great. Question on free cash flow. Can you comment on the free cash flow conversion? How should we think about the guidance for this year, but also going forward as some of the restructuring costs come off? How do we think about the free cash flow conversion going forward?
Yeah, ultimately, free cash flow is critical for us. It's been an area where we've been looking to improve that over the past couple years. I think we've made good progress on that. For this coming year, and as an early perspective or early insight into 2027 that we provided just a month ago in our earnings, is that we expect for 2027 to be able to grow free cash flow from where we exit this year by about 10%-15% in this coming year. I think we are going to have the opportunity to do that in three primary areas. To get the business sold that we did this past year, the divestiture of LS&H and some of the other wind-down activity, there was a higher amount of one-time or transactional costs that were a drag on free cash flow.
That's going to go down significantly in this coming year. That's the first area. Secondly, from an interest, cash interest or interest expense perspective, we made some debt reduction throughout the course of the year, but then we had the large tender offer and repayment and repurchase that we just completed here in November. We'll get the full year benefit of that in 2027. That's the second area where we'll see, make a continued improvement and progress from 2026 to 2027. Lastly, just from a CapEx perspective as well, we talked about that historically, LS&H was a little higher user of CapEx and investment than our other businesses. We've been up over 10% of CapEx as a percentage of revenue in the past. We'll see that get under 10% in 2027, so that'll be the third area.
The three of those combined will get us to a 10%-15% growth on free cash flow in 2027.
That's great color. I think what is underappreciated is this 10%-15% of free cash flow growth despite divesting off your Life Sciences & Healthcare business.
Yeah.
Despite divesting off, you're driving higher free cash flow conversion.
Yeah.
That's very helpful. How do you think about using the proceeds? As you said, you have a tender offer out, so maybe if you can provide more color on that, but also, how do you plan to use your strong free cash flow next year and over the midterm?
Yeah, we've signaled that in 2026, the priority was around using our free cash flow to pay down debt, and we've already signaled that's going to be the priority for 2027 as well. With that, nothing is coming due in 2027, but the next two near-term maturities are our 2028 notes and our 2029 notes. It's really a matter of looking at those from what is the economic perspective for both of them, also then just which are the maturities that are coming due the quickest, and what's our estimates of free cash flow generation over the next couple of years.
You saw in the tender offer we just did, we went out at about an 80/20 split between the 2028s and the 2029s, had good participation in that tender offer, ended up upsizing it by another $33 million to go out with a total $533 million debt repurchase. But there's more that we'll continue to do. We gave an indication that for 2027, we expect to end the year about 3.5 x leverage, and to do that, we need to focus our free cash flows on debt repayment as we move through 2027. We'll have a focus on just the near-term maturities, which will become the 2028s as we get into 2027, and that will be an area we'll focus on through the coming year.
Okay. That is helpful. Just switching back and going to the AI initiatives, we talked about a lot of those different AI initiatives, but I was just wondering, outside of IPOne and Web of Science Research Intelligence, how do you think about the other AI initiatives or the roadmap for AI initiatives over the midterm?
The headlines are IPOne and Web of Science Research Intelligence, but we have additional AI initiatives going on the product side all across. We have won a big contract from the USPTO, TrademarkVision. This is AI capabilities of a new product. We won an award for RiskMark, another product that we have on the IP side, and we constantly improve the others on the A&G side. We have Web of Science Research Intelligence, the prime one on research. We have few AI new product initiatives, one we call ProQuest Intelligence on the content side. We have a new product coming up called SkyRiver on the software side. So there are some additional in each area or sub-area of ours, sub-segment, there are additional AI initiatives ongoing.
Let us not forget, many of us have come from product engineering background, as opposed to. So we have a lot of passion to product innovation. That is our roots for many of us.
That is great.
Yeah.
We'll keep it there. Thank you very much.
Yeah.
Thanks, everyone.
Sure. Yeah.
Thanks for coming.
Thank you for your attention.
Thank you.
Thank you, Ashish.
Thank you, Mike.